Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.47 UNCHANGED

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

34 35 Next >

2 Growth Stocks That Could Double Your Money, According to Wall Street ↗

October 15, 2023

Find out why investment bank analysts are pounding the table on these stocks.

Via The Motley Fool

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years ↗

October 14, 2023

These two gene-editing stocks could be diamonds in the rough.

Via The Motley Fool

Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row ↗

October 11, 2023

Via Benzinga

Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares ↗

October 10, 2023

Via Benzinga

Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You? ↗

October 10, 2023

Wood has outperformed the market so far this year.

Via The Motley Fool

2 Bargain Growth Stocks to Buy Hand Over Fist ↗

September 28, 2023

Both stocks have declined in recent times.

Via The Motley Fool

Cathie Wood Goes Shopping For Stock of Jack Dorsey's Block — Ark Invest Bolsters Portfolio With Archer Aviation, CRISPR Shares ↗

October 09, 2023

Via Benzinga

3 No-Brainer Growth Stocks to Buy in October ↗

October 07, 2023

The time is right to invest in these great stocks.

Via The Motley Fool

2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street ↗

October 05, 2023

The analysts who follow these stocks have some big expectations for the year ahead.

Via The Motley Fool

Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price ↗

October 04, 2023

Via Benzinga

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich ↗

October 03, 2023

Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.

Via InvestorPlace

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗

October 03, 2023

The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.

Via The Motley Fool

2 Top Biotech Stocks to Buy in October ↗

October 03, 2023

Growth catalysts lie ahead for both of these players.

Via The Motley Fool

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics ↗

October 02, 2023

The better of the pair should be able to beat Bluebird Bio.

Via The Motley Fool

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

October 01, 2023

These companies are helping change medicine; they could make boatloads of money along the way.

Via The Motley Fool

3 Cathie Wood Stocks Set to Explode Higher ↗

October 01, 2023

Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside.

Via InvestorPlace

Futurescape: Betting Big on These 3 Next-Gen Tech Stocks ↗

October 01, 2023

These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains.

Via InvestorPlace

3 No-Brainer Growth Stocks to Buy in October ↗

October 01, 2023

These three top mid-cap stocks could be poised for a long-tailed growth spurt.

Via The Motley Fool

Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock ↗

September 29, 2023

Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.

Via Benzinga

Why Editas Medicine Stock Is Soaring Today ↗

September 29, 2023

Investors are cheering a big analyst upgrade for the gene-editing stock.

Via The Motley Fool

If I Could Only Buy 3 Stocks in 2023, I'd Pick These ↗

September 29, 2023

These stocks have what it takes to grow in leaps and bounds.

Via The Motley Fool

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment ↗

September 28, 2023

The FDA is within three months of making a decision on the first-ever CRISPR-based drug.

Via Investor's Business Daily

Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher ↗

September 27, 2023

These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.

Via InvestorPlace

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects ↗

September 27, 2023

Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗

September 27, 2023

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

2 Cathie Wood Stocks to Buy Hand Over Fist Right Now ↗

September 24, 2023

These two high-tech stocks could dramatically outperform the broader market in the years ahead.

Via The Motley Fool

$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years ↗

September 21, 2023

I favor holding onto these players for the long term to truly benefit from their earnings potential.

Via The Motley Fool

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio ↗

September 20, 2023

These two biotechs have a lot in common, but one is much better capitalized.

Via The Motley Fool

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.